Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Camrelizumab + AS in Advanced Pancreatic Cancer
NCT05218889Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Chinese PLA General Hospital. Started Aug 2021; status: recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05218889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218889.